ASCO 2026: A potential functional cure in endometrial cancer, with Eric Richards

For GSK, ASCO 2026 was about long-term follow-up data, with new data from ongoing trials of Jemperli and Blenrep. The four-year Jemperli data is especially exciting, as it showed that more than half of patients on a combination of Jemperli and chemotherapy had long-term low-risk status, suggestive of a functional cure. Eric Richards, SVP and head of oncology project leadership at GSK, spoke with pharmaphorum Editor in Chief Jonah Comstock on the sidelines of the show. More from pharmaphorum: Website: https://pharmaphorum.com/ Full videos: / @pharmaphorum Newsletter: https://pharmaphorum.com/register LinkedIn: / pharmaphorum-media About pharmaphorum: pharmaphorum.com, and its associated digital magazine Deep Dive, is a leading online destination for healthcare and pharmaceutical industry news, insight and debate. #ASCO #ASCO2026 #pharma #pharmaphorum #GSK #Jemperli #Blenrep #oncology #cancertreatment